IP Library › Granted Patent US 10,238,662
Granted Patent B2
US 10,238,662 · App. 15/119,344 · Granted Mar 26, 2019

Needle assisted jet injection administration of testosterone compositions

Inventors: Paul K. Wotton (Newtown, PA); Hermanus L. Jooste (Wayne, PA); Kaushik J. Dave (Edison, NJ); Jon Jaffe (Annandale, NJ)
Assignee: ANTARES PHARMA, INC.
A61K31/568A61M5/2033A61M5/30A61M5/3204A61M2005/206A61M2005/2013A61M2005/2073A61P5/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,662
App. No.
15/119,344
Granted
Mar 26, 2019
Kind
B2
Abstract

The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Claims (27)

1. A method of obtaining steady state average blood concentration of testosterone comprising:

repeatedly injecting a dose of testosterone over a prescribed time period such that a steady state blood plasma level of testosterone is obtained after three or more doses.

2. The method of claim 1 , wherein the dose is selected from between 50 mg, 75 mg and 100 mg.

3. The method of claim 2 , wherein the concentration of the injected dose is 100 mg/ml, 150 mg/ml or 200 mg/ml.

4. The method of claim 1 , wherein the dose is between 50 mg and 100 mg.

5. The method of claim 1 , wherein the prescribed time period is one week.

6. The method of claim 1 , wherein the steady state blood plasma level of testosterone is reached after the fourth dose.

7. The method of claim 1 , wherein the steady state blood plasma level of testosterone is reached after the fifth dose.

8. The method of claim 1 , further comprising:

injecting another dose after the steady state blood plasma level of testosterone is reached.

9. The method of claim 8 , wherein the another dose is the same as the dose injected prior to reaching the steady state blood plasma level of testosterone.

10. The method of claim 1 , wherein once the steady state blood plasma level of testosterone is reached, the average blood plasma level obtained after injecting a subsequent dose or doses is less than + or −30% of the average blood plasma level of testosterone obtained during an immediately preceding prescribed time period.

11. The method of claim 1 , wherein the steady state blood plasma level of testosterone after the repeated injections is about 800 ng/dl to about 1100 ng/dl.

12. The method of claim 1 , wherein the steady state blood plasma level of testosterone after the repeated injections is about 500 ng/dl to about 800 ng/dl.

13. The method of claim 1 , wherein the steady state blood plasma level of testosterone after the repeated injections is about 350 ng/dl to about 500 ng/dl.

14. The method of claim 1 , wherein the dose of testosterone is injected subcutaneously.

15. The method of claim 1 , wherein the dose of testosterone is injected intramuscularly.

16. The method of claim 8 , wherein the another dose is injected subcutaneously.

17. The method of claim 8 , wherein the another dose is injected intramuscularly.

18. The method of claim 8 , wherein the another dose is injected intradermally.

19. A method of obtaining steady state average blood concentration of testosterone comprising:

repeatedly injecting a dose of testosterone subcutaneously over a prescribed time period such that a steady state blood plasma level of 300 ng/dl to about 1800 ng/dl of testosterone is obtained after three of more doses.

20. The method of claim 19 , wherein the steady state blood plasma level of testosterone is about 350 ng/dl to about 500 ng/dl.

21. The method of claim 1 , wherein the dose of testosterone is injected via a powered injector.

22. The method of claim 8 , wherein the another dose is different than the dose.

23. The method of claim 9 , wherein the another dose is injected via a different route of administration.

24. The method of claim 8 , wherein the steady state blood plasma level of testosterone is maintained at or above a therapeutically effective level while the another dose is injected.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2022
From: WOTTON, PAUL K.; JOOSTE, HERMANUS L.; DAVE, KAUSHIK J.; JAFFE, JON
To: ANTARES PHARMA, INC.
Reel/Frame 059451/0397 →
Continuity (2)
Provisional Application 61941875 · Feb 19, 2014
Related Publication 20170007621A1 · Jan 12, 2017
Cited By (2)
US 12,453,819 US 12,527,802